Table 2.
Disease-free survival analysis of clinicopathological data and percentage genome change of 120 patients with hepatocellular carcinoma
| Clinicopathological factor | Log-rank test, P value | Cox regression analysis, P value | HR (95%CI) |
| Age (yr), ≤ 49 (22.5%) vs > 49 (77.5%) | 0.004a | 0.169 | 0.674 (0.384-1.183) |
| Sex (M/F), M (81.7%) vs F (19.3%) | 0.146 | ||
| Tumor size (cm), ≤ 4.5 (69.2%) vs > 4.5 (30.8%) | 0.001a | 0.012a | 1.959 (1.160-3.309) |
| Satellite lesions (%), Yes (7.5%) vs No (92.5%) | 0.088 | 0.013a | 2.900 (1255-6.702) |
| Vascular invasion (%), Yes (28.3%) vs No (71.7%) | 0.240 | ||
| Grading I, II, III, IV (%), III & IV (43.3%) vs I & II (56.7%) | 0.004a | 0.063 | 1.626 (0.974-2.717) |
| Margin < 0.5 cm (%), ≤ 0.5 cm (47.5%) vs > 0.5 cm (52.5%) | 0.210 | ||
| Cirrhosis (%), Yes (54.2%) vs No (45.8%) | 0.258 | ||
| AFP (100 ng/mL), £100 (77.5%) vs > 100 (22.5%) | 0.006a | 0.462 | 1.244 (0.695-2.227) |
| Alkaline phosphatase (120 U/L), ≤ 120 (88.3%) vs > 120 (11.7%) | 0.016a | 0.042a | 1.976 (1.025-3.808) |
| Staging I/II, II (40.0%) vs I (60.0%) | 0.104 | ||
| Percentage genome changed (60%), ≥ 60% (7.5%) vs < 60% (92.5%) | 0.004a | 0.031a | 2.346 (1.080-5.097) |
a
P < 0.05, statistically significant. AFP: α-fetoprotein; HCC: Hepatocellular carcinoma; HR: Hazard ratio; CI: Confidence interval; M: Male; F: Female.